1.Prevalence and confounders of chronic endometritis diagnosed using CD138 in patients with recurrent implantation failure
Hye Jeong HUE ; Hyunji CHOI ; Hyun Kyoung LEE ; Jung Ryeol LEE ; Byung Chul JEE ; Chang Woo CHOO ; Seul Ki KIM
Clinical and Experimental Reproductive Medicine 2024;51(2):163-169
		                        		
		                        			 Objective:
		                        			This retrospective study aimed to investigate the prevalence of chronic endometritis, diagnosed using CD138 immunohistochemistry, among infertile women and to assess the association between chronic endometritis and recurrent implantation failure (RIF). 
		                        		
		                        			Methods:
		                        			In total, 266 patients who underwent hysteroscopy due to infertility between 2019 and 2020 were included in the analysis. Of these, 136 patients with RIF and 130 non-RIF patients were included in the study. CD138 immunohistochemistry test results, blood biomarkers (including natural killer cells, white blood cells, and the lymphocyte-to-neutrophil ratio), and data on pregnancy outcomes were obtained. If the CD138 test yielded a positive result, the patients received antibiotic treatment. 
		                        		
		                        			Results:
		                        			The overall proportion of CD138-positive patients was 32.7% (87/266). The CD138 positivity rate was not related to the number of cycles with implantation failure. In the RIF patient group, no significant associations were found between CD138 positivity and peripheral blood markers. The clinical pregnancy rates were similar between infertile women treated with antibiotics for chronic endometritis and those without chronic endometritis. 
		                        		
		                        			Conclusion
		                        			To improve the pregnancy rate in infertile patients, it may be helpful to combine CD138 testing with other laboratory tests and administer antibiotic treatment if the result is positive. 
		                        		
		                        		
		                        		
		                        	
2.Recommendations for Adult Immunization by the Korean Society of Infectious Diseases, 2023: Minor Revisions to the 3rd Edition
Won Suk CHOI ; Joon Young SONG ; Ki Tae KWON ; Hyo-Jin LEE ; Eun Ju CHOO ; Jihyeon BAEK ; BumSik CHIN ; Woo Joo KIM ; Mi Suk LEE ; Wan Beom PARK ; Sang Hoon HAN ; Jun Yong CHOI ; Joon Sup YEOM ; Jin-Soo LEE ; Hee-Jung CHOI ; Young Hwa CHOI ; Dong-Gun LEE ; Jung-Hyun CHOI ; Hee Jin CHEONG ;
Infection and Chemotherapy 2024;56(2):188-203
		                        		
		                        			
		                        			 The Korean Society of Infectious Diseases has been regularly developing guidelines for adult immunization since 2007. In 2023, the guidelines for the following seven vaccines were revised: influenza, herpes zoster, pneumococcal, tetanus-diphtheria-pertussis (Tdap), human papillomavirus (HPV), meningococcal, and rabies vaccines. For the influenza vaccine, a recommendation for enhanced vaccines for the elderly was added. For the herpes zoster vaccine, a recommendation for the recombinant zoster vaccine was added. For the pneumococcal vaccine, the current status of the 15-valent pneumococcal conjugate vaccine and 20-valent PCV was described. For the Tdap vaccine, the possibility of using Tdap instead of tetanus-diphtheria vaccine was described. For the HPV vaccine, the expansion of the eligible age for vaccination was described. For the meningococcal vaccine, a recommendation for the meningococcal B vaccine was added. For the rabies vaccine, the number of pre-exposure prophylaxis doses was changed. This manuscript documents the summary and rationale of the revisions for the seven vaccines. For the vaccines not mentioned in this manuscript, the recommendations in the 3rd edition of the Vaccinations for Adults textbook shall remain in effect. 
		                        		
		                        		
		                        		
		                        	
3.Risk Factors for Infertility in Korean Women
Juyeon LEE ; Chang-Woo CHOO ; Kyoung Yong MOON ; Sang Woo LYU ; Hoon KIM ; Joong Yeup LEE ; Jung Ryeol LEE ; Byung Chul JEE ; Kyungjoo HWANG ; Seok Hyun KIM ; Sue K. PARK
Journal of Korean Medical Science 2024;39(10):e85-
		                        		
		                        			 Background:
		                        			Female infertility is a crucial problem with significant implications for individuals and society. In this study, we explore risk factors for infertility in Korean women. 
		                        		
		                        			Methods:
		                        			A total of 986 female patients who visited six major infertility clinics in Korea were recruited from April to December 2014. Fertile age-matched controls were selected from two nationwide survey study participants. Conditional logistic regression after age-matching was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) of each risk factor for infertility. 
		                        		
		                        			Results:
		                        			Women with a body mass index (BMI) < 18.5 kg/m2 had 1.35 times higher odds of infertility (OR, 1.35; 95% CI, 1.03–1.77), while those with a BMI ≥ 25.0 kg/m2 had even higher odds (OR, 2.06; 95% CI, 1.61–2.64) compared to women with a normal BMI (18.5 kg/m2 ≤ BMI < 25 kg/m 2 ). Ever-smokers exhibited 4.94 times higher odds of infertility compared to never-smokers (95% CI, 3.45–8.85). Concerning alcohol consumption, women who consumed ≥ 7 glasses at a time showed 3.13 times significantly higher odds of infertility than those who consumed ≤ 4 glasses at a time (95% CI, 1.79–5.48). Lastly, women with thyroid disease demonstrated 1.44 times higher odds of infertility compared to women without thyroid disease (95% CI, 1.00–2.08). 
		                        		
		                        			Conclusion
		                        			Female infertility in Korea was associated with underweight, obesity, smoking, alcohol consumption, and thyroid disease. 
		                        		
		                        		
		                        		
		                        	
4.The applicability of noncontact sensors in the field of rehabilitation medicine
Yoo Jin CHOO ; Jun Sung MOON ; Gun Woo LEE ; Wook-Tae PARK ; Min Cheol CHANG
Journal of Yeungnam Medical Science 2024;41(1):53-55
		                        		
		                        			
		                        			 A noncontact sensor field is an innovative device that can detect, measure, or monitor physical properties or conditions without direct physical contact with the subject or object under examination. These sensors use a variety of methods, including electromagnetic, optical, and acoustic technique, to collect information about the target without physical interaction. Noncontact sensors find wide-ranging applications in various fields such as manufacturing, robotics, automobiles, security, environmental monitoring, space industry, agriculture, and entertainment. In particular, they are used in the medical field, where they provide continuous monitoring of patient conditions and offer opportunities in rehabilitation medicine. This article introduces the potential of noncontact sensors in the field of rehabilitation medicine. 
		                        		
		                        		
		                        		
		                        	
6.Korean Medication Algorithm Project for Bipolar Disorder 2022:Comparisons with Other Treatment Guidelines
Jong-Hyun JEONG ; Won-Myong BAHK ; Young Sup WOO ; Bo-Hyun YOON ; Jung Goo LEE ; Won KIM ; InKi SOHN ; Sung-Yong PARK ; Se-Hoon SHIM ; Jeong Seok SEO ; IL Han CHOO ; Chan-Mo YANG ; Myung Hun JUNG ; Duk-In JON ; Moon-Doo KIM
Clinical Psychopharmacology and Neuroscience 2023;21(1):32-48
		                        		
		                        			
		                        			 The objective of this study was to compare recommendations of the Korean Medication Algorithm Project for Bipolar Disorder 2022 (KMAP-BP 2022) with other recently published guidelines for treating bipolar disorder. We reviewed a total of six recently published global treatment guidelines and compared treatment recommendation of the KMAP-BP 2022 with those of other guidelines. For initial treatment of mania, there were no significant differences across treatment guidelines. All guidelines recommended mood stabilizer (MS) or atypical antipsychotic (AAP) monotherapy or a combination of an MS with an AAP as a first-line treatment strategy in a same degree for mania. However, the KMAP-BP 2022 recommended MS + AAP combination therapy for psychotic mania, mixed mania and psychotic depression as treatment of choice. Aripiprazole, quetiapine and olanzapine were the first-line AAPs for nearly all phases of bipolar disorder across guidelines. Some guideline suggested olanzapine is a second-line options during maintenance treatment, related to concern about long-term tolerability. Most guidelines advocated newer AAPs (asenapine, cariprazine, long-acting injectable risperidone, and aripiprazole once monthly) as first-line treatment options for all phases while lamotrigine was recommended for depressive and maintenance phases. Lithium and valproic acid were commonly used as MSs in all phases of bipolar disorder. KMAP-BP 2022 guidelines were similar to other guidelines, reflecting current changes in prescription patterns for bipolar disorder based on accumulated research data. Strong preference for combination therapy was characteristic of KMAP-BP 2022, predominantly in the treatment of psychotic mania, mixed mania and psychotic depression. 
		                        		
		                        		
		                        		
		                        	
7.Retraction to “Korean Version of Mini Mental Status Examination for Dementia Screening and Its Short Form”
Tae Hui KIM ; Jin Hyeong JHOO ; Joon Hyuk PARK ; Jeong Lan KIM ; Seung Ho RYU ; Seok Woo MOON ; Il Han CHOO ; Dong Woo LEE ; Jong Chul YOON ; Yeon Ja DO ; Seok Bum LEE ; Moon Doo KIM ; Ki Woong KIM
Psychiatry Investigation 2023;20(2):182-182
		                        		
		                        		
		                        		
		                        	
8.Association of Arrhythmia in the Elderly Patients on Combination Therapy of CYP3A4 Substrates and Inhibitors with the Korean Claims Data
Tae Woo KIM ; Junhyuk CHANG ; Eunjung CHOO ; Rae Woong PARK ; Sukhyang LEE
Korean Journal of Clinical Pharmacy 2023;33(4):242-253
		                        		
		                        			 Background:
		                        			Arrhythmia due to QT prolongation is one of the most serious adverse events with drug interactions in the elderly. This study  aimed  to  examine  the  incidence  of  arrhythmia  in  Korean  elderly  patients  who  administered  both  cytochrome  P450  3A4 (CYP3A4) substrates and inhibitors.  
		                        		
		                        			Methods:
		                        			Patients using CYP3A4 substrate and inhibitor were selected from the 2017 elderly patient dataset (the Korean Health Insurance Review and Assessment Service - Aged Population Sample). Selection criteria were patients with a medication possession ratio over 80%, medication duration of at least 7 days, and a follow-up period of 3 months or more. The patient’s basic information is age, gender, health insurance type, and comorbidities. The top 50 drug pairs and comorbidity with  high-incidence  arrhythmia  were  presented.   
		                        		
		                        			Results:
		                        			 In   patien ts  with  drug  combin ation s  for  over  7  days,  there  were  981 incidences of arrhythmia, and 351 incidences in those with combinations for over 30 days. The comorbidities of congestive heart failure and myocardial infarction had a significant association with incidence of arrhythmia. Among patients with 7 days or longer, the drug pairs [substrates-inhibitors] with significant adjusted odds ratio (aOR) were [propranolol-cimetidine] (aOR, 2.25; 95% confidence interval [CI], 1.66-3.04). Among patients with 30 days or longer, the drug pairs with significant aOR were [tramadolamiodarone] (aOR, 2.87; 95% CI, 1.97-4.19).  
		                        		
		                        			Conclusions
		                        			In elderly patients, the incidence of arrhythmia was high with drug interactions of CYP3A4 substrates and inhibitors. The comorbidity of congestive heart failure was the risk factor. 
		                        		
		                        		
		                        		
		                        	
9.The Korean Medication Algorithm Project for Depressive Disorder 2021: Comparisons with Other Treatment Guidelines
Young Sup WOO ; Won-Myong BAHK ; Jeong Seok SEO ; Young-Min PARK ; Won KIM ; Jong-Hyun JEONG ; Se-Hoon SHIM ; Jung Goo LEE ; Seung-Ho JANG ; Chan-Mo YANG ; Sheng-Min WANG ; Myung Hun JUNG ; Hyung Mo SUNG ; Il Han CHOO ; Bo-Hyun YOON ; Sang-Yeol LEE ; Duk-In JON ; Kyung Joon MIN
Clinical Psychopharmacology and Neuroscience 2022;20(1):37-50
		                        		
		                        			
		                        			 The Korean Medication Algorithm Project for Depressive Disorder (KMAP-DD) first was published in 2002, and has been revised four times, in 2006, 2012, 2017, and 2021. In this review, we compared recommendations from the recently revised KMAP-DD 2021 to four global clinical practice guidelines (CPGs) for depression published after 2010. The recommendations from the KMAP-DD 2021 were similar to those from other CPGs, although there were some differences. The KMAP-DD 2021 reflected social culture and the healthcare system in Korea and recent evidence about pharmacotherapy for depression, as did other recently published evidence-based guidelines. Despite some intrinsic limitations as an expert consensus-based guideline, the KMAP-DD 2021 can be helpful for Korean psychiatrists making decisions in clinical settings by complementing previously published evidence-based guidelines, especially for some clinical situations lacking evidence from rigorously designed clinical trials. 
		                        		
		                        		
		                        		
		                        	
10.Frequency of reoperation in patients who underwent breast reconstruction using Allergan implants after an interview about breast implant-associated anaplastic large cell lymphoma
Jae Woo LEE ; Seung Hyun KIM ; Min Wook KIM ; Dae Kyun JEONG ; Seong Hwan BAE ; Hyun Yul KIM ; Youn Joo JUNG ; Ki Seok CHOO ; Kyung Jin NAM ; Su Bong NAM
Archives of Aesthetic Plastic Surgery 2022;28(2):61-66
		                        		
		                        			 Background:
		                        			In recent years, breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) has emerged as an important concern. At our institution, patients who received breast reconstruction using Allergan implants were informed individually about BIA-ALCL. The present study analyzed correlations between patients’ level of satisfaction with their breast shape and whether they chose to undergo reoperation (implant removal or replacement). 
		                        		
		                        			Methods:
		                        			Breast reconstruction with Allergan implants was performed between December 2014 and April 2018. In total, 107 patients were interviewed, excluding those who had died, were unreachable, or had already undergone reoperation. The mean follow-up period was 53 months (range, 26–73 months). 
		                        		
		                        			Results:
		                        			After the interviews, 68 patients postponed reoperation, 29 had their implant replaced, and 10 had their implant removed. Nearly one-fifth (18.9%) of patients who were satisfied with their breast shape (13 out of 69) underwent reoperation due to anxiety over ALCL. Meanwhile, 68.4% of patients who were not satisfied due to capsular contracture or scar contracture (26 out of 38) underwent reoperation. Sixteen of the 30 patients who received postoperative radiotherapy (53.3%) chose to undergo reoperation. 
		                        		
		                        			Conclusions
		                        			Satisfaction with the cosmetic outcomes of implant placement played a meaningful role in patients’ decisions to undergo reoperation. This tendency may be linked to postoperative radiotherapy, which is a major contributor to complications such as contracture. Nonetheless, a substantial proportion of patients who were satisfied with the outcomes chose to undergo reoperation due to concerns regarding ALCL. 
		                        		
		                        		
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail